Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
group B streptococcus capsular polysaccharide II conjugated to CRM197
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
group B streptococcus capsular polysaccharide II conjugated to CRM197 is a monovalent conjugate vaccine component developed by Pfizer. It consists of the capsular polysaccharide (CPS) from Group B Streptococcus (GBS) serotype II covalently linked to CRM197, a non-toxic mutant of the diphtheria toxin. This conjugation converts the T-cell independent polysaccharide antigen into a T-cell dependent antigen, thereby enhancing immunogenicity and inducing immunological memory, which is particularly important for protecting infants through maternal immunization. This specific conjugate is one of the six components of Pfizer's hexavalent GBS vaccine candidate, PF-06760805 (GBS6), which targets the most prevalent serotypes causing invasive GBS disease globally. The vaccine is currently in Phase 3 clinical trials for the prevention of invasive GBS disease in neonates and young infants via immunization of pregnant women.
- Other names
- GBS Type II-CRM197 conjugateGBS II-CRM197group B streptococcus capsular polysaccharide II conjugated to CRM197
02
Targets
GBS CPS (Group B Streptococcus capsular polysaccharide)
Beyond the preview
Go deeper on group B streptococcus capsular polysaccharide II conjugated to CRM197.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on group B streptococcus capsular polysaccharide II conjugated to CRM197.